PMI Releases Position Paper for COP8: Addresses Need for Harm-Reduction Strategies
Philip Morris International Inc. (PMI) (NYSE:PM) is today publishing its position paper on its views surrounding the Eighth Session of the Conference of Parties (COP8) to the World Health Organization (WHO) Framework Convention of Tobacco Control (FCTC). With more than one billion people expected to be smoking in 2025, PMI is urging the WHO, the hundreds of delegates convening in Geneva this week, and the wider public health community to embrace the potential of innovative alternatives to cigarettes in order to achieve the UN’s sustainable development goals for non-communicable diseases as quickly as possible.
Available on PMI.com, the position paper acknowledges that smoking prevalence is in decline, but argues that the pace of that decline could be much faster.
In the paper PMI states: “The landscape of tobacco and nicotine products has evolved significantly over recent years. Not all tobacco products are the same with respect to their health risks. Moreover, rapid innovation offers opportunities to accelerate the downward trajectory of smoking prevalence.”
Ultimately, PMI aims to stop selling cigarettes entirely and is confident that this can happen in less than a century if smokers who would otherwise continue to smoke are proactively encouraged to switch to less harmful alternatives, which already exist but are either not well known or in some cases restricted.
Where these products have been adopted, for instance, in countries such as Japan and the U.K., there have been unprecedented declines in cigarette sales. Progress in these countries signals the potential for great change across the globe and is the core reason why PMI has publicly committed its future to being smoke-free, and continues to develop new science-based technologies and innovations that offer better alternatives to men and women who would otherwise continue to smoke.
PMI’s policy making recommendations published today include:
- Policies must continue to dissuade minors, ex-smokers, and non-smokers from using tobacco- and nicotine-containing products, while making better alternatives to cigarettes available to adults who smoke.
- Tobacco control policies should encompass tobacco-harm reduction strategies as well as supply and demand measures that encourage smokers who would otherwise continue to smoke to switch to better alternatives.
- There should be thorough, independent verification of manufacturers’ products and science to assess how ENDS [electronic nicotine delivery systems] and novel and emerging tobacco and nicotine products can support policies to reduce smoking prevalence.
- There should be national and global surveillance systems to study market trends. This surveillance should include data on product usage, including switching rates associated with different tobacco and nicotine products, to enable accurate reporting of smoking prevalence and the use of ENDS and novel and emerging tobacco products.
- Incentives should encourage investment and continuous research and development of less harmful alternatives, including the establishment of quality and performance standards for smoke-free products.
- Mechanisms should be established to enable transparent interaction and consultation between governments and producers of emerging tobacco and nicotine products.
# # #
Notes to Editors
To view the full position statement please click here.
Philip Morris International
+41 (0)58 242 4500
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
SIAE MICROELETTRONICA Outperforms Telefónica 10Gbps E-band Tests to Power 5G Backhauling10.12.2018 08:00 | Pressemelding
Telefónica a global leader mobile operator and SIAE MICROELETTRONICA a leader in wireless transport technology have put to the test the high capacity 10Gbps wireless links to enhance the backhauling network for the future advent of 5G. The millimetre-wave point-to-point radio operating at 80GHz E band carrier, offers the lowest transport latency and the highest wireless capacity of 10Gbps over a single channel, satisfying the strict 5G requirements. Telefónica successfully field tested SIAE MICROELETTRONICA millimetre-wave radio solution in two use cases: 10Gbps point-to-point links addressing urban applications and the multicarrier link aggregation addressing the sub-urban applications, pushing high capacity connectivity to longer distances. “SIAE MICROELETTRONICA and Telefónica have cooperated over multiple projects all aiming to satisfy the 5G backhaul requirements. From microwave SDN applications to the introduction of state of the art millimetre-wave radio, once again crossing tog
Fishawack Acquires Creative Consultancy Blue Latitude Health10.12.2018 07:00 | Pressemelding
The Fishawack Group of Companies, one of the world’s largest independent medical communications and medical marketing organizations, has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181209005023/en/ Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row from left to right). (Photo: Business Wire) “In 2016, we set out our vision to form a major new force in the global creative agency space that would make us as strong in the creative arena as we already are in medical communications,” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “With three acquisitions in this space in the last 16 months, I think we’ve firmly announced our intention t
Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer10.12.2018 06:00 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics. His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe. The Board has also appointed Gregg Alton as interim Chief Executive Officer for the period of January 1, 2019 until Mr. O’Day’s start date of March 1, 2019. Mr. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel and in August of this year, was appointed Chief Patient Officer. “Following a comprehensive search, the Board became convinced that Dan is the right leader to bring Gilead into the future,” said John C. Martin, PhD, Chairman, Gilea
Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity8.12.2018 14:10 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing HERCEPTIN® 1 (trastuzumab), to reference trastuzumab (TRZ) by antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is a key mechanism of action for trastuzumab. The study results are being presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. For the study, patients with HER2 positive early or locally advanced breast cancer were randomly assigned to receive SB3 or TRZ concurrently with chemotherapy. Patients then underwent surgery followed by treatment with SB3 or TRZ. Following completion of such therapy, 367 patients participated in a long-term follow-up study, 186 of whom were treated with SB3 and 181 of whom were treated with TRZ. Within the group of 181 patients who received TRZ, 126 patients who were exposed to at least
Harvest Health & Recreation, Inc. to hold Conference Call to Discuss Q3 2018 Results and Performance Outlook7.12.2018 19:00 | Pressemelding
Harvest Health & Recreation, Inc. (HARV: CSE) will hold its Third Quarter 2018 earnings conference call on: Tuesday, December 11, 2018 8:30 AM (Eastern Time) Participating on the call to review Harvest Health & Recreation’s Third Quarter 2018 financial and operating results will be Jason Vedadi, Executive Chairman, Steve White, Chief Executive Officer, and Steve Gutterman, President. Third quarter results are available at www.harvestinc.com/news. To participate in the conference call, please dial: US toll free +1-866-777-2509 Canada toll free +1-866-605-3852 UK toll free +44-080-823-89064 International dial in +1-412-317-5413 Registration is required; please dial in at least ten minutes prior to the scheduled start time. Webcast: https://services.choruscall.com/links/harv181211.html The conference call will be available for replay for 3 months at: https://services.choruscall.com/links/harv181211.html. About Harvest Health & Recreation, Inc. Harvest Health & Recreation, Inc. is one of t
David Hall Wows Industry with New Technology Solution for Space Exploration7.12.2018 14:01 | Pressemelding
David Hall is one of history’s rare technological visionaries with the imagination and technical wherewithal to recognize a problem, conceive a solution, and then build something that works. On December 6 at the U.S. Chamber of Commerce’s event, LAUNCH: Industry Taking Off, David Hall presented his world-changing solution to a longstanding problem: how to carry materials and people into space safely, reliably, and efficiently. The audience of industry, military, and policy representatives heard from Hall as well as keynote remarks from Secretary of the Air Force, Heather Wilson; NASA Administrator, Jim Bridenstine; Under Secretary of Defense for Research and Engineering, Michael Griffin; NOAA Deputy Administrator, Dr. Neil Jacobs; and Commerce Secretary, Wilbur Ross. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181207005226/en/ Velodyne Lidar, Inc. Founder and CEO David Hall (Photo: Business Wire) Hall’s proposal involves